Skip to content
Screener

OnKure Therapeutics, Inc. OKUR Q1 2026 earnings

Reported May 5, 2026 · Before market open

EPS-$1.11Miss by $0.30
Revenue estimate$166.7K
EPS estimate-$0.81

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$166.7K
EPS estimate-$0.36

Financials

Q1 2026

Income statement

See full
Operating income-$15.6M+8.1%
Net income-$15.2M+4.8%
EPS (diluted)-$1.11+6.7%

Balance sheet

See full
Cash & equivalents$192.1M+98.7%
Total debt$409.0K-57.2%
Total equity$184.4M+103%
Total assets$198.7M+98.9%

Cash flow

See full
Operating cash flow-$12.9M+7.6%
CapEx$5.0K-72.2%
Free cash flow-$12.9M+7.7%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$178.25M-2.0%
Enterprise value-$13.45M-116%

Returns & leverage

See full
Return on equity-42.7%—
Debt / equity0×0.0×
Current ratio13.8×+2.6×

FAQ

When did OnKure Therapeutics, Inc. report Q1 2026 earnings?
OnKure Therapeutics, Inc. (OKUR) reported Q1 2026 earnings on May 5, 2026 before market open.
What were OnKure Therapeutics, Inc.'s Q1 2026 revenue and EPS?
OnKure Therapeutics, Inc. reported eps of $-1.11 for Q1 2026.
Did OnKure Therapeutics, Inc. beat estimates in Q1 2026?
EPS missed the consensus estimate of $-0.81 by $0.30.
How did OnKure Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 6.7% from $-1.19.
Where can I find OnKure Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-206396) and the 10-Q periodic report (0001193125-26-206345) directly on SEC EDGAR. The filing index links above go to sec.gov.